Today early stage partnering is a core component of both biotech and pharmaceutical business strategy, allowing companies to access promising new and emerging compounds and technologies. Dealmaking in the pharmaceutical industry is constantly growing; big pharmaceutical companies are forecast to receive around 40-50% of their revenue from in-licensed products by 2010 (Pharmalicensing, 2006). The balance of dealmaking activity has also moved, from the later stages of development to the early stages, where deals have not only increased in number but value too. The average early stage deal value has risen from US$65.3 million in 2001 to US$125.1 million in 2005 (Burrill & Company, 2006).

NextGen is engaged in the development and commercial licensure of novel therapeutic proteins that disrupt the growth of cancers. Our patented drug and product portfolio includes a prostate cancer target and a breast cancer target as well as a promising acquisition pipeline. All of NextGen’s product candidates target disease indications which represent a significant unmet need, as well as having substantial potential market values.

NextGen intends to follow an outlicensing strategy, whereby programmes are outlicensed at preclinical, or Phase I, to organizations which have the necessary infrastructure to bring the products to market.

Therapeutic Focus – NextGen indication areas

1. Prostate cancer
2. Breast cancer
3. Colorectal cancer

BACK TO TOP